Home › Treatment-Resistant Depressive Disorder › NCT07623135
Lumateperone for Late-Life Depression
Who can join
Ages 60 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age \>=60 * Current unipolar non-psychotic major depression determined by SCID-5 * MADRS score \>=20 at screening and \>=18 at baseline * Treatment-resistance defined as documented history of non-response to at least two oral medications of adequate dose and duration in this episode or previous episode, OR clinician determination that treatment augmentation is appropriate * Currently taking oral antidepressant prescribed at least minimum therapeutic dose and for at least six weeks duration * MMSE score of \>/=24 Exclusion Criteria: * Dementia * High risk for suicide, defined as a 4 or 5 on C-SSRS (indicating active suicidal ideation with current or recent intent or plan), and unable to be managed safely in the clinical trial. Urgent psychiatric referral will be made in these cases. * High risk alcohol use: defined as a score of 6 or more on the AUDIT-C * Medically inappropriate for participation as determined by PIs.
About the study
The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S. Food and Drug Administration to treat Major Depressive Disorder in adults who are also taking another antidepressant medication. This study will compare lumateperone (Caplyta) to placebo (a sugar pill without medication).
What is being tested
- Lumateperone (drug)
- Placebo (drug)
Sponsor: Eric Lenze · Participants: 100 · Started: Sep 1, 2026
Contact the study team
- Angela Stevens · Phone: 314-362-6291
- Julie Schweiger · Phone: 314-362-3153
Official record on ClinicalTrials.gov — NCT07623135
Locations in the U.S.
| Arizona | University of Arizona, Tucson |
| Missouri | Washington University School of Medicine, St Louis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.